Advice
Following a full submission:
carglumic acid (Carbaglu®) is accepted for use within NHS Scotland.
Indication under review: hyperammonaemia due to isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia.
The available clinical evidence for carglumic acid, although limited, suggests that plasma ammonia is reduced rapidly to non-toxic levels in life-threatening situations where rapid initiation of treatment is essential.
Download detailed advice136KB (PDF)
Medicine details
- Medicine name:
- carglumic acid (Carbaglu)
- SMC ID:
- 899/13
- Indication:
- For the treatment of hyperammonaemia due to isovaleric acidemia / hyperammonaemia due to methymalonic acidaemia / hyperammonaemia due to propionic acidaemia.
- Pharmaceutical company
- Orphan Europe (UK) Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 October 2013